Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

References

• Lisa CS. Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2010;22:623–6
   PubMed Web of Science ®Google Scholar
• Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52:857–61.
   PubMed Web of Science ®Google Scholar
• Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999;78:139–47.
   PubMed Web of Science ®Google Scholar
• Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14:R22.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Robinson H, Masi AT. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum. 1971;14:249–58.
   PubMed Web of Science ®Google Scholar
• Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006;25:234–9.
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230–7.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43.
   PubMed Web of Science ®Google Scholar
• Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35–42.
   PubMed Web of Science ®Google Scholar
• Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J-F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63:3439–47.
   PubMedGoogle Scholar
• Yu K-H, Wu Y-JJ, Kuo C-F, See L-C, Shen Y-M, Chang H-C, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595–601.
   PubMed Web of Science ®Google Scholar
• Hengstman GJD, ter Laak HJ, Vree Egberts WTM, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65:1635–8.
   PubMed Web of Science ®Google Scholar
• Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73:420–8.
   PubMed Web of Science ®Google Scholar
• Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TW. Clinical and serological associations of anti-Ku antibody. J Rheumatol. 1999;26:563–7.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Tonello M, Bendo R, et al. [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients]. Reumatismo. 2005;57:22–8.
   PubMedGoogle Scholar
• Hengstman GJD, Vree Egberts WTM, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006;65:242–5.
   PubMed Web of Science ®Google Scholar
• Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, Hirano T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40:215–7.
   PubMed Web of Science ®Google Scholar
• Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel J-L, et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore). 2012;91:95–102.
   PubMed Web of Science ®Google Scholar
• Szodoray P, Hajas A, Kardos L, Dezso B, Soos G, Zold E, et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21:1412–22.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.
   PubMedGoogle Scholar
• Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37:100–9.
   PubMed Web of Science ®Google Scholar
• Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49:361–9.
   PubMed Web of Science ®Google Scholar
• Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–41.
   PubMed Web of Science ®Google Scholar
• Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12:210–7.
   PubMed Web of Science ®Google Scholar
• Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010;62:1328–34.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49:433–40.
   PubMed Web of Science ®Google Scholar
• Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26:436–9.
   PubMed Web of Science ®Google Scholar
• Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford). 2004;43:603–8.
   PubMed Web of Science ®Google Scholar
• Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol. 1993;161:359–66.
   PubMed Web of Science ®Google Scholar
• Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281–90.
   PubMed Web of Science ®Google Scholar
• Engel A, Hohlfeld R. The polymyositis and dermatomyositis syndrome. In: Engel AG F-AC, ed. Myology: Basic and Clinical. 3rd ed. New York: McGraw-Hill, Medical Pub. Division; 2004:1321–66.
   Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.
   PubMed Web of Science ®Google Scholar
• Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. In: Gordon PA, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2012:CD003643.
   Google Scholar
• Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13:311–23.
   PubMed Web of Science ®Google Scholar
• Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011;13:119–30.
   PubMed Web of Science ®Google Scholar
• Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13.
   PubMed Web of Science ®Google Scholar
• Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23:665–78.
   PubMed Web of Science ®Google Scholar
• Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60:1825–30.
   PubMedGoogle Scholar
• Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;57:1008.
   PubMed Web of Science ®Google Scholar
• Nzeusseu A, Brion F, Lefèbvre C, Knoops P, Devogelaer JP, Houssiau FA. Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol. 1999;17:441–6.
   PubMed Web of Science ®Google Scholar
• Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88:83–105.
   PubMed Web of Science ®Google Scholar
• Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13:225–9.
   PubMed Web of Science ®Google Scholar
• Engel AG, Hohlfeld, R. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology: Basic and Clinical. 3rd ed. New York: McGraw-Hill; 2004.
   Google Scholar
• Henriksson K, Standstedt P. Polymyositis-treatment and prognosis. A study of 107 patients. Acta Neurol Scand. 1982;65:280–300.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.
   PubMed Web of Science ®Google Scholar
• Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59:99–112.
   PubMed Web of Science ®Google Scholar
• Marie I. Morbidity and Mortality in Adult Polymyositis and Dermatomyositis. Curr Rheumatol Rep. 2012;14:275–85.
   PubMed Web of Science ®Google Scholar
• Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve. 1998;21:1668–72.
   PubMed Web of Science ®Google Scholar
• Bronner IM, van der Meulen MFG, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456–61.
   PubMed Web of Science ®Google Scholar
• Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739–45.
   PubMed Web of Science ®Google Scholar
• Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. 1976;61:485–92.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Polymyositis, Dermatomyositis, and Inclusion-Body Myositis. N Engl J Med. 1991;325:1487–98.
   PubMed Web of Science ®Google Scholar
• Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76:234–42.
   PubMed Web of Science ®Google Scholar
• Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J. 1968;123:158–73.
   PubMedGoogle Scholar
• Yates DA. Steroid myopathy. Rheumatol Phys Med. 1971;11:28–33.
   PubMedGoogle Scholar
• Goldling DN, Murray SM, Pearce GW, Thompson M. Corticosteroid myopathy. Ann Phys Med. 1961;6:171–7.
   PubMedGoogle Scholar
• Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18:155–66.
   PubMed Web of Science ®Google Scholar
• Kagen LA. The Inflammatory Myopathies. New York: Humana Press; 2009.
   Google Scholar
• Lovitt S, Moore SL, Marden FA. The use of MRI in the evaluation of myopathy. Clin Neurophysiol. 2006;117:486–95.
   PubMed Web of Science ®Google Scholar
• Walton JN, Adams RD. Polymyositis. Edinburgh: E. & S. Livingstone, Ltd; 1958.
   Google Scholar
• van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382–9.
   PubMed Web of Science ®Google Scholar
• Oddis C V, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory poly myositis with inter stitial lung disease. Lancet. 1999;353:1762–3.
   PubMed Web of Science ®Google Scholar
• Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855–9.
   PubMed Web of Science ®Google Scholar
• Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24:45–8.
   PubMed Web of Science ®Google Scholar
• Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet (London, England). 1989;1:1063–6.
   PubMedGoogle Scholar
• Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–46.
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1446–51.
   PubMed Web of Science ®Google Scholar
• Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65–9.
   PubMed Web of Science ®Google Scholar
• Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245–7.
   PubMed Web of Science ®Google Scholar
• Ramanan A V, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570–8.
   PubMed Web of Science ®Google Scholar
• Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36:67–71.
   PubMed Web of Science ®Google Scholar
• Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32:754–7.
   PubMed Web of Science ®Google Scholar
• Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365–9.
   PubMed Web of Science ®Google Scholar
• Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–9.
   PubMed Web of Science ®Google Scholar
• Miller JAL, Walsh Y, Samiaden S, Lecky BRF. Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. (ABN Abstracts). J Neurol Neurosurg Psychiatry. 2002;73:222–3.
   Web of Science ®Google Scholar
• Mitsui T, Kuroda Y, Ueno S-I, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg. 2011;111:188–94.
   PubMed Web of Science ®Google Scholar
• Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R, et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010;29:443–5.
   PubMed Web of Science ®Google Scholar
• Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254–9.
   PubMed Web of Science ®Google Scholar
• Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30:1021–8.
   PubMed Web of Science ®Google Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology. 2005;44:386–9.
   PubMed Web of Science ®Google Scholar
• Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43:491–6.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. N Engl J Med. 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–93.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37–41.
   PubMed Web of Science ®Google Scholar
• Marie I, Menard J-F, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–55.
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev. 2009;9:124–7.
   PubMed Web of Science ®Google Scholar
• Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78:1009–15.
   PubMed Web of Science ®Google Scholar
• Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum. 2011;63:3142–52.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.
   PubMed Web of Science ®Google Scholar
• Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139:441–3.
   PubMed Web of Science ®Google Scholar
• Rios Fernández R, Callejas Rubio J-L, Sánchez Cano D, Sáez Moreno J-A, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27:1009–16.
   PubMed Web of Science ®Google Scholar
• Chung L, Genovese MC, Fiorentino DF. A Pilot Trial of Rituximab in the Treatment of Patients With Dermatomyositis. Arch Dermatol. 2007;143:763–7.
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum. 2005;52:601–7.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56:3107–11.
   PubMed Web of Science ®Google Scholar
• Chiu YE, Co DO. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol. 2011;28:357–67.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65:1233–6.
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.
   PubMed Web of Science ®Google Scholar
• Coyle K, Pokrovnichka A, French K. A randomized, double-blind, placebo- controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res. 2008;58:S293.
   Google Scholar
• Hengstman GJD, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59:159–63.
   PubMed Web of Science ®Google Scholar
• Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50:1344–6.
   PubMed Web of Science ®Google Scholar
• Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Jt Bone Spine. 2011;78:431–2.
   PubMed Web of Science ®Google Scholar
• Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160:520–2.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Fujikawa K, Kawakami A, Tamai M, Yamasaki S, Ida H, et al. Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy. Mod Rheumatol. 2010;20:496–9.
   PubMed Web of Science ®Google Scholar
• Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol. 1991;18:1693–700.
   PubMed Web of Science ®Google Scholar
• Yao L, Gai N. Fat-corrected T2 measurement as a marker of active muscle disease in inflammatory myopathy. AJR Am J Roentgenol. 2012;198:W475–81.
   PubMed Web of Science ®Google Scholar
• Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008;59:214–21.
   PubMedGoogle Scholar
• Bonin CC, da Silva BSP, Mota LM, de Carvalho JF. Severe and refractory myositis in mixed connective tissue disease: a description of a rare case. Lupus. 2010;19:1659–61.
   PubMed Web of Science ®Google Scholar
• Oddis C V., Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607–15.
   PubMed Web of Science ®Google Scholar
• Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913–20.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Amjadi SS, Paulus HE, International Myositis Assessment and Clinical Studies Group. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey. Clin Rheumatol. 2012;31:1163–8.
   PubMed Web of Science ®Google Scholar
• Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol. 1996;23:1380–4.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Reed AM, Ytterberg SR. The Myositis Activities Profile – initial validation for assessment of polymyositis/dermatomyositis in the USA. J Rheumatol. 2012;39:2134–41.
   PubMed Web of Science ®Google Scholar
• Brandão M, Marinho A. Idiopathic inflammatory myopathies: Definition and management of refractory disease. Autoimmun Rev. 2011;10:720–4.
   PubMed Web of Science ®Google Scholar
• Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60:3436–46.
   PubMed Web of Science ®Google Scholar
• Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor Necrosis Factor Inhibitor–Associated Dermatomyositis. Arch Dermatol. 2010;146:780–4.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29:563–6.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev. 2011;10:679–84.
   PubMed Web of Science ®Google Scholar
• Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. N Engl J Med. 1992;326:1380–4.
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;53:155–65.
   PubMed Web of Science ®Google Scholar
• Marie I, Ménard J-F, Hachulla E, Chérin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum. 2011;41:48–60.
   PubMed Web of Science ®Google Scholar
• Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186–8.
   PubMed Web of Science ®Google Scholar
• Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73:1123–9.
   PubMedGoogle Scholar
• Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96–128.
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Stenström CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol. 2000;29:295–301.
   PubMed Web of Science ®Google Scholar
• Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol. 1993;20:1340–4.
   PubMed Web of Science ®Google Scholar
• Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol. 1998;37:196–200.
   PubMedGoogle Scholar
• Wiesinger GF, Quittan M, Graninger M, Seeber A, Ebenbichler G, Sturm B, et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol. 1998;37:1338–42.
   PubMedGoogle Scholar
• Alexanderson H, Stenström CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford). 1999;38:608–11.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57:768–77.
   PubMed Web of Science ®Google Scholar
• Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7.
   PubMed Web of Science ®Google Scholar
• Palace J, Losseff N, Clough C. Isolated dysphagia due to polymyositis. Muscle Nerve. 1993;16:680–1.
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Levesque H, Reumont G, Ducrotte P, Cailleux N, et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol. 1999;26:2706–9.
   PubMed Web of Science ®Google Scholar
• Hafejee A, Coulson IH. Dysphagia in dermatomyositis secondary to bladder cancer: rapid response to combined immunoglobulin and methylprednisolone. Clin Exp Dermatol. 2005;30:93–4.
   PubMed Web of Science ®Google Scholar
• Mii S, Niiyama S, Kusunoki M, Arai S, Katsuoka K. Cyclosporine A as treatment of esophageal involvement in dermatomyositis. Rheumatol Int. 2006;27:183–5.
   PubMed Web of Science ®Google Scholar
• Hirano F, Tanaka H, Nomura Y, Matsui T, Makino Y, Fukawa E, et al. Successful treatment of refractory polymyositis with pulse intravenous cyclophosphamide and low-dose weekly oral methotrexate therapy. Intern Med. 1993;32:749–52.
   PubMed Web of Science ®Google Scholar
• Kagen LJ, Hochman RB, Strong EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630–6.
   PubMedGoogle Scholar
• Vencovský J, Rehák F, Pafko P, Jirásek A, Valesová M, Alusík S, et al. Acute cricopharyngeal obstruction in dermatomyositis. J Rheumatol. 1988;15:1016–8.
   PubMed Web of Science ®Google Scholar
• Nagano H, Yoshifuku K, Kurono Y. Polymyositis with dysphagia treated with endoscopic balloon dilatation. Auris Nasus Larynx. 2009;36:705–8.
   PubMed Web of Science ®Google Scholar
• Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14:264–74.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1354–60.
   PubMed Web of Science ®Google Scholar
• Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–6.
   PubMed Web of Science ®Google Scholar
• Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51:1278–84.
   PubMed Web of Science ®Google Scholar
• Shi J, Xu W, Liu H, Tian X, Feng R, Xu Z, et al. Clinico-pathological manifestations in interstitial lung diseases associated with polymyositis-dermatomyositis. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31:250–4.
   PubMedGoogle Scholar
• Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380–7.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58–64.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Tanaka M, Kobayashi H, Nakazono T, Satoh T, Fukuno Y, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol. 2008;35:260–9.
   PubMed Web of Science ®Google Scholar
• Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341–7.
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51:1563–70.
   PubMed Web of Science ®Google Scholar
• Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol. 2013;23:872–83.
   PubMed Web of Science ®Google Scholar
• Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64:1602–10.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496–502.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012;51:800–4.
   PubMed Web of Science ®Google Scholar
• Horai Y, Isomoto E, Koga T, Okada A, Kawashiri S, Tamai M, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol. 2013;23:190–4.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Ishii W, Matsuda M, Katoh N, Tazawa K, Sekijima Y, et al. Coadministration of cyclosporin A with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis. Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:43–52.
   PubMedGoogle Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2012;22:625–9.
   PubMed Web of Science ®Google Scholar
• Matsuki Y, Yamashita H, Takahashi Y, Kano T, Shimizu A, Itoh K, et al. Diffuse alveolar damage in patients with dermatomyositis: a six-case series. Mod Rheumatol. 2012;22:243–8.
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–26.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology. 2007;46:124–30.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201–6.
   PubMed Web of Science ®Google Scholar
• Gupta R, Wayangankar SA, Targoff IN, Hennebry TA. Clinical cardiac involvement in idiopathic inflammatory myopathies: A systematic review. Int J Cardiol. 2011;148:261–70.
   PubMed Web of Science ®Google Scholar
• Bazzani C, Cavazzana I, Ceribelli A, Vizzardi E, Dei Cas L, Franceschini F. Cardiological features in idiopathic inflammatory myopathies. J Cardiovasc Med. 2010;11:906–11.
   Google Scholar
• Allanore Y, Vignaux O, Arnaud L, Puéchal X, Pavy S, Duboc D, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis. 2006;65:249–52.
   PubMed Web of Science ®Google Scholar
• Sénéchal M, Crête M, Couture C, Poirier P. Myocardial dysfunction in polymyositis. Can J Cardiol. 2006;22:869–71.
   PubMed Web of Science ®Google Scholar
• Karaca NE, Aksu G, Yeniay BS, Kutukculer N. Juvenile dermatomyositis with a rare and remarkable complication: sinus bradycardia. Rheumatol Int. 2006;27:179–82.
   PubMed Web of Science ®Google Scholar
• Jankowska M, Butto B, Debska-Slizień A, Rutkowski B. Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int. 2007;27:775–80.
   PubMed Web of Science ®Google Scholar
• Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine. 2008;75:334–7.
   PubMed Web of Science ®Google Scholar
• Tahiri L, Guignard S, Pinto P, Duclos M, Dougados M. Antisynthetases syndrome associated with right heart failure. Joint Bone Spine. 2009;76:715–7.
   PubMed Web of Science ®Google Scholar
• el-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46:560–5.
   PubMed Web of Science ®Google Scholar
• Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol. 2009;28:979–84.
   PubMed Web of Science ®Google Scholar
• Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol. 1995;131:1381–5.
   PubMedGoogle Scholar
• Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol. 2002;138:114–6.
   PubMedGoogle Scholar
• Callen JP. Cutaneous Manifestations of Dermatomyositis and Their Management. Curr Rheumatol Rep. 2010;12:192–7.
   PubMedGoogle Scholar
• Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7:341–51.
   PubMed Web of Science ®Google Scholar
• Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25:112–34.
   PubMed Web of Science ®Google Scholar
• Lampropoulos CE, D’Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis. 2005;64:1376–7.
   PubMed Web of Science ®Google Scholar
• Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12:50–2.
   PubMed Web of Science ®Google Scholar
• Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15:35–9.
   PubMedGoogle Scholar
• García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004;209:247–8.
   PubMed Web of Science ®Google Scholar
• Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004;20:230–4.
   PubMed Web of Science ®Google Scholar
• Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19:367.
   PubMed Web of Science ®Google Scholar
• Cohen JB. Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int J Dermatol. 2002;41:182–4.
   PubMed Web of Science ®Google Scholar
• Kawachi Y, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, Otsuka F. Pruritic poikilodermatous eruption associated with dermatomyositis: successful treatment with dapsone. Eur J Dermatol. 2012;22:289–90.
   PubMed Web of Science ®Google Scholar
• Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol. 1999;26:457–9.
   PubMedGoogle Scholar
• Peake MF, Perkins P, Elston DM, Older SA, Vinson RP. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis. 1998;62:89–93.
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Pyrpasopoulou A, Kartali N, Zamboulis C. Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis. Clin Rheumatol. 2007;26:1198–200.
   PubMed Web of Science ®Google Scholar
• Hornung T, Ko A, Tüting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37:139–42.
   PubMed Web of Science ®Google Scholar
• Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27:1542–5.
   PubMed Web of Science ®Google Scholar
• Mehregan DR, Su WP. Cyclosporine treatment for dermatomyositis/polymyositis. Cutis. 1993;51:59–61.
   PubMed Web of Science ®Google Scholar
• Grau JM, Herrero C, Casademont J, Fernández-Solà J, Urbano-Márquez A. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol. 1994;21:381–2.
   PubMed Web of Science ®Google Scholar
• Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27:1469–71.
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–36.
   PubMed Web of Science ®Google Scholar
• Berger RG, Featherstone GL, Raasch RH, McCartney WH, Hadler NM. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1987;83:72–6.
   PubMedGoogle Scholar
• Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol. 1998;25:716–20.
   PubMedGoogle Scholar
• Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23:2152–5.
   PubMed Web of Science ®Google Scholar
• Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford). 2000;39:333–4.
   PubMed Web of Science ®Google Scholar
• Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol. 2005;15:102–4.
   PubMed Web of Science ®Google Scholar
• Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol. 1988;124:1721–2.
   PubMedGoogle Scholar
• Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2010;77:70–2.
   PubMed Web of Science ®Google Scholar
• Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28:135–40.
   PubMed Web of Science ®Google Scholar
• Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32:1837–9.
   PubMed Web of Science ®Google Scholar
• Skuterud E, Sydnes OA, Haavik TK. Calcinosis in dermatomyositis treated with probenecid. Scand J Rheumatol. 1981;10:92–4.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006;33:1691–3.
   PubMed Web of Science ®Google Scholar
• Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: Response to intravenous immunoglobulin. J Am Acad Dermatol. 2009;60:1076–7.
   PubMed Web of Science ®Google Scholar
• Touimy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80:108–9.
   PubMed Web of Science ®Google Scholar
• Vitale A, Delia G, La Torre F, Calcagno G, D’Alcontres FS. Massive gluteal calcinosis in a 10-year-old girl with juvenile dermatomyositis: successful surgical management. Plast Reconstr Surg. 2009;124:456e–8e.
   PubMed Web of Science ®Google Scholar
• Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica. 1990;180:212–6.
   PubMedGoogle Scholar
• Mebazaa A, Boussen H, Nouira R, Gamoudi A, Rahal K, Kamoun MR, et al. Dermatomyositis and breast cancer: a multicenter Tunisian retrospective study of 13 cases. Tunis Med. 2011;89:18–22.
   PubMedGoogle Scholar
• András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35:438–44.
   PubMed Web of Science ®Google Scholar
• Hirai T, Tsujihata M, Ueda T, Nonomura N, Okuyama A. A case of polymyositis associated with adrenal carcinoma. Int J Urol. 2007;14:952–3.
   PubMed Web of Science ®Google Scholar
• Takahashi F, Tsuta K, Nagaoka T, Miyamoto H, Saito Y, Amano H, et al. Successful resection of dermatomyositis associated with thymic carcinoma: report of a case. Surg Today. 2008;38:245–8.
   PubMed Web of Science ®Google Scholar
• Masuda H, Urushibara M, Kihara K. Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol. 2003;169:1084.
   PubMed Web of Science ®Google Scholar
• Yoshinaga A, Hayashi T, Ishii N, Ohno R, Watanabe T, Yamada T. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol. 2005;12:593–5.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Hosokawa M, Hirohashi S, Arimura Y, Endo T, Denno R, et al. Epstein-Barr virus-associated gastric cancer in a patient with dermatomyositis. Intern Med. 2001;40:96–9.
   PubMed Web of Science ®Google Scholar
• Caratta PR, Mafort T, Pamplona M, Schau B, Estrella RR, Ramos RC. Paraneoplastic vesiculobullous dermatomyositis with synchronic prostate and tongue tumors: case report. Rev Bras Reumatol. 2011;51:394–6.
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22:1807.
   Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017;69:2271–82.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al.; International Myositis Classification Criteria Project consortium, The Euromyositis register, and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64
   PubMed Web of Science ®Google Scholar